Page 48 - ஒன்றுபட்டது நாடுகள் நிலையான வளர்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
생태계 훼손에 70년도 안걸렸다…지구 짓밟는 인류 발자국
joins.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from joins.com Daily Mail and Mail on Sunday newspapers.
Hilton Releases 2020 ESG Report, Reinforcing Commitment to Positive Global Impact
sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology
Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology
Potential for regional tuberculosis vaccines, novel personalized cancer vaccines, and improving checkpoint inhibition therapy
Helsinki, Finland, 19 April 2021: Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights for the proprietary ‘PeptiBAC’ technology from the University of Helsinki, Finland.
PeptiBAC uses the BCG (Bacillus Calmette-Guèrin) vaccine as a backbone for delivery of disease specific peptides. The technology has preventative potential in infectious diseases, specifically tuberculosis (TB, caused by Mycobacterium tuberculosis (MTB)), as well therapeutic potential in canc
Valo Therapeutics Acquires University of Helsinki s PeptiBAC Cancer and Infectious Disease Vaccination Technology
Potential for regional tuberculosis vaccines, novel personalized cancer vaccines, and improving checkpoint inhibition therapy
News provided by
Share this article
Share this article
HELSINKI, April 19, 2021 /PRNewswire/ Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights for the proprietary PeptiBAC technology from the University of Helsinki, Finland.
PeptiBAC uses the BCG (Bacillus Calmette-Guèrin) vaccine as a backbone for delivery of disease specific peptides. The technology has preventative potential in infectious diseases, specifically tuberculosis (TB, caused by Mycobacterium tuberculosis (MTB)), as well therapeutic potential in cancer. The BGC vaccine, one of the earliest immunotherapies, has been widely used globa
keen attention to detail and data accuracy is required.
● Excellent communication skills: Strong writing ability, skilled in creating knowledge products such as policy briefs, papers, guidance notes and other pieces directed at multiple audiences; ability to work under tight deadlines, juggling multiple competing tasks and prioritising demands is highly desired.
● Strong team player: Strong interpersonal skills; ability to interact with high-level individuals across a range of organisations; customer-orientation and sound judgment; ability to consistently demonstrate a professional manner in dealing with individuals at all levels, both internally and externally to the organisation; team player and flexible as tasks and priorities shift; ability to self-start and troubleshoot without supervision; ability to work independently and in teams in a small office environment; demonstrated ability to excel in a multi-cultural environment highly desired.
vimarsana © 2020. All Rights Reserved.